Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124
Expand allThis document outlines details of PBS-subsidised elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Multiple myeloma (MM) quick reference - Continuing
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Table 1
|
Restrictions |
Treatment type |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self- serve |
|
Initial Newly diagnosed PB291 form |
Monotherapy |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Newly diagnosed PB200 form |
Dual therapy with dexamethasone |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Newly diagnosed PB293 form |
Triple therapy (this drug, bortezomib and dexamethasone) |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Balance of Supply Newly diagnosed (cycles 5-6 or cycles 5-8) |
Triple therapy (this drug, bortezomib and dexamethasone) |
Telephone Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Progressive disease PB158 form |
Monotherapy or dual combination therapy with dexamethasone |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial |
Dual therapy (this drug and dexamethasone) |
Written Electronic S100: pomalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Triple therapy (this drug, carfilzomib and dexamethasone) |
Telephone Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial |
Triple therapy (this drug, bortezomib and dexamethasone) |
Telephone Electronic S100: pomalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Triple therapy (this drug, lenalidomide and dexamethasone) |
Telephone Electronic S100: elotuzumab |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Dual therapy (this drug and dexamethasone) |
Telephone Electronic S100: selinexor |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma
|
Triple therapy (this drug, bortezomib and dexamethasone) |
Telephone Electronic S100: selinexor |
No |
OPA |
Not specified |
Yes |
Multiple myeloma (MM) quick reference - Continuing
Table 2
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Table 3
|
Step |
Treatment phase |
Drug combination |
Treatment cycle |
Quantity & repeats |
Authority level |
|
1 |
Initial |
lenalidomide & dexamethasone & bortezomib |
Cycle 1 - 4 |
|
Written (PB293) Electronic |
|
2 |
Balance |
lenalidomide & dexamethasone & bortezomib |
Cycle 5 - 8 |
|
Telephone Electronic |
|
3 |
Continuing dual therapy (meeting criteria) |
lenalidomide & dexamethasone |
Cycle 9 and beyond |
|
Telephone Electronic |
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Table 4
|
Step |
Treatment phase |
Drug combination |
Treatment cycle |
Quantity & repeats |
Authority level |
|
1 |
Initial |
lenalidomide & dexamethasone & bortezomib |
Cycle 1 - 4 |
|
Written (PB293) Electronic |
|
2 |
Balance |
lenalidomide & dexamethasone & bortezomib |
Cycle 5 - 6 |
|
Telephone Electronic |
|
3 |
If ineligible for SCT Initial newly diagnosed dual therapy If post SCT Initial newly diagnosed monotherapy |
Ineligible for SCT lenalidomide & dexamethasone Post SCT lenalidomide |
N/A |
Ineligible for SCT
Post SCT
|
Ineligible for SCT Written (PB200) Electronic Post SCT Written (PB291) Electronic |